FDA Inspection 1220703 — Eagle Pharmaceuticals, Inc.

Eagle Pharmaceuticals, Inc. — FEI 3011077747

The FDA completed an inspection of Eagle Pharmaceuticals, Inc. on Oct 13, 2023 in Woodcliff Lake, NJ. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.

Inspection details

Classification
No Action Indicated (NAI)
End Date
Oct 13, 2023
Fiscal Year
2024
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
Woodcliff Lake, NJ (United States)

Additional details

Postmarket Adverse Drug Experience (PADE)

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.